Core Points - Company has signed a licensing agreement with Swiss Rockets AG to grant exclusive rights to its CoolMPS sequencing technology and general sequencing technology for commercialization outside the Asia-Pacific and Greater China regions [1][2] - The agreement allows Swiss Rockets to develop and commercialize CoolMPS products while the company and its subsidiary will provide technical support and product development [2][3] - The licensing deal is expected to generate at least $120 million in licensing fees, significantly improving the company's profitability and cash flow while allowing it to focus on its core technologies [3] Licensing Agreement Details - The licensing agreement includes exclusive rights to CoolMPS technology and non-exclusive rights to general sequencing technology for use in the CoolMPS product field [2] - The company retains all rights in the Asia-Pacific and Greater China markets, enabling it to concentrate resources on its Standard MPS technology and core markets [3] - The agreement is aligned with the company's strategic development direction, allowing for the realization of technology value without additional R&D investment [3] Financial Implications - The transaction is projected to yield significant immediate profits and long-term stable cash flow, enhancing the company's financial position [3] - The licensing fees from the agreement are expected to contribute positively to the company's overall profitability [3]